Investors are always looking for growth in small-cap stocks like Imprimis Pharmaceuticals Inc (NASDAQ:IMMY), with a market cap of $33.27M. However, an important fact which most ignore is: how ...

Turing Pharmaceuticals sparked nationwide outrage and government investigations by raising the cost of Daraprim, a drug for treating AIDS and cancer, from $13.50 a capsule to $750 last month. This ...

Mark Baum is the CEO of Imprimis Pharmaceuticals Inc (NASDAQ:IMMY), which has recently grown to a market capitalization of $35.53M. Recognizing whether CEO incentives are aligned with shareholders is ...

Please provide your email address to receive an email when new articles are posted on . Well, no one is going to accuse the folks at Imprimis of trying to fly under the radar, eh? For the second time ...

(Reuters) - Compounding pharmacy Imprimis Pharmaceuticals Inc said on Wednesday it plans to make a cheaper alternative to Retrophin Inc's kidney stone drug, Thiola. Retrophin, under former Chief ...

Imprimis Pharmaceuticals Inc IMMY wants to stop egregious drug pricing issues, and Mallinckrodt PLC MNK is its next target. Imprimis announced it will pursue a lower priced alternative to Mallinckrodt ...

Imprimis Pharmaceuticals, Inc. (NASDAQ:IMMY), which is focused on the commercialization of drug formulations utilizing the FDA 505(b)(2) drug development pathway, today announced that as part of the ...

NEW YORK (Reuters) - Imprimis Pharmaceuticals Inc (IMMY.O), the compounding pharmacy that makes a $1 copycat of Turing Pharmaceuticals' high priced Daraprim treatment, sees an opportunity to build a ...

The conservative newsletter Imprimis has nearly 2 million subscribers, which is surprising because almost no one has ever heard of it. To judge by its presence on the national media radar, Imprimis is ...

When a generic drug formulation goes from $13.50 per pill to $750 each, the company making it is essentially putting a "Kick Me" sign on their back. But unless you've been offline or away from the ...